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Abstract Tau is a microtubule-associated protein that is
abnormally hyperphosphorylated in the filamentous lesions that
define a number of neurodegenerative diseases collectively
referred to as tauopathies. We previously showed that stress-
activated protein (SAP) kinases phosphorylate tau protein at
many of the hyperphosphorylated sites in vitro. Here we have
developed a system to study the effects of five SAP kinases
(SAPK1c/JNK1, SAPK2a/p38K, SAPK2b/p38L, SAPK3/p38Q
and SAPK4/p38N) on tau phosphorylation in intact cells. All
kinases phosphorylated tau, albeit at different efficiencies. Tau
was a good substrate for SAPK3/p38Q and SAPK4/p38N, a
reasonable substrate for SAPK2b/p38L and a relatively poor
substrate for SAPK2a/p38K and SAPK1c/JNK1. These findings
indicate that the aberrant activation of SAP kinases, especially
SAPK3/p38Q and SAPK4/p38N, could play an important role in
the abnormal hyperphosphorylation of tau that is an invariant
feature of the tauopathies. ß 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Filamentous deposits made of the microtubule-associated
protein tau constitute a de¢ning neuropathological feature
of Alzheimer’s disease and other neurodegenerative diseases,
such as progressive supranuclear palsy, corticobasal degener-
ation, Pick’s disease and the inherited frontotemporal demen-
tia and Parkinsonism linked to chromosome 17 (FTDP-17)
[1]. The discovery of mutations in the tau gene in FTDP-17
has established that dysfunction of tau protein is su⁄cient to
cause neurodegeneration and dementia [2^4]. Human brain
tau exists as six isoforms that are alternatively spliced from
a single gene [5]. They di¡er by having three or four conserved
repeats towards the carboxy-terminus and no, one or two
insertions in the amino-terminal half. The repeats constitute
the microtubule-binding domains of tau [6].
Abnormal hyperphosphorylation of tau protein is an invar-
iant feature in diseases with ¢lamentous tau deposits [1]. It is
an early event that appears to precede assembly into ¢laments
[7,8]. Hyperphosphorylation renders tau unable to interact
with microtubules which may facilitate its self-assembly
[9,10]. Extensive protein chemical and immunochemical stud-
ies have identi¢ed over 20 hyperphosphorylated amino acids
in ¢lamentous tau from Alzheimer’s disease brain, almost all
of which £ank the repeat region [11,12]. Approximately half
of these sites are serine/threonine-prolines. Phosphorylation at
many of these sites occurs in a signi¢cant fraction of tau from
developing brain and a small fraction of tau from adult hu-
man brain [13^15]. However, some residues are only phos-
phorylated in ¢lamentous tau [16,17].
Hyperphosphorylation of tau could result from an in-
creased activity of tau kinases or the decreased activity of
tau phosphatases. Based largely on in vitro experiments, mi-
togen-activated protein (MAP) kinase [18^20], stress-activated
protein (SAP) kinases [21,22], neuronal cdc2-like kinase
(NCLK), also known as cyclin-dependent kinase 5 [23,24],
glycogen synthase kinase-3 (GSK3) [25,26] and dual-speci¢c-
ity tyrosine-phosphorylated and regulated kinase [27] are can-
didate protein kinases for the hyperphosphorylation of tau at
serine/threonine-prolines and protein phosphatase 2A is a can-
didate phosphatase [20]. Since a number of protein kinases are
capable of phosphorylating tau at many relevant sites in vitro,
it is important to identify which of these kinases phosphory-
late tau in vivo. Previous studies have demonstrated the phos-
phorylation of tau by GSK3 [28,29] and NCLK [30^32] in
intact cells. By contrast, activated MAP kinase produced
only a small increase in tau phosphorylation in intact cells
[28,33]. Here, we have examined the ability of the SAP kinases
SAPK1c/JNK1, SAPK2a/p38K, SAPK2b/p38L, SAPK3/p38Q
and SAPK4/p38N to phosphorylate human tau protein in
transfected COS cells.
2. Materials and methods
2.1. Expression constructs
The previously described [34,35] cDNA clones encoding SAPK1c/
JNK1, SAPK2a/p38K, SAPK2b/p38L, SAPK3/p38Q and SAPK4/p38N,
as well as clones encoding the upstream activators MAP kinase ki-
nase-4 (MKK4) and MKK6 were subcloned into the eukaryotic ex-
pression vector pSG5 (Stratagene). A c-myc tail was added to the
carboxy-termini of SAPK2b/p38L, SAPK3 and SAPK4. The cDNA
encoding htau40 (the 441 amino acid isoform of human brain tau) [5]
was also subcloned into pSG5.
2.2. Cell culture and transfection
COS-7 cells were grown in 25 cm2 £asks in Dulbecco’s modi¢ed
Eagle’s medium containing glutamax (Life Technologies) supple-
mented with 10% foetal calf serum in a 95% O2/5% CO2 incubator
at 37‡C and transiently transfected with 10 Wg/ml plasmid DNA using
DEAE-dextran chloroquine. After 48 h, cells transfected with the tau
0014-5793 / 02 / $22.00 ß 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 2 4 6 0 - 2
*Corresponding author. Fax: (44)-1223-402197.
E-mail address: mg@mrc-lmb.cam.ac.uk (M. Goedert).
1 Present address: Universite¤ d’Artois, Faculte¤ des Sciences
Jean Perrin, rue Jean Souvraz, 62300 Lens, France.
FEBS 25907 28-3-02
FEBS 25907 FEBS Letters 515 (2002) 151^154
construct alone, or with the tau, SAPK and SAPKK constructs were
treated with 0.5 M sorbitol for 30 min in serum-free medium. Cells
were harvested in phosphate-bu¡ered saline, pH 7.4, at 4‡C and cen-
trifuged. The pellets were resuspended in 50 mM Tris^NaCl, boiled
for 2 min and re-centrifuged. Protein concentrations were determined
in the supernatants (Bio-Rad protein assay).
2.3. Immunoblots
Electrophoresis and immunoblotting were performed as described
[36]. Brie£y, an equal amount of protein from each sample was loaded
onto 10% SDS^PAGE. Following transfer and blocking, membranes
were incubated with the primary antibody for 90 min at room temper-
ature. Horseradish peroxidase-conjugated secondary antibody (Sigma
Fine Chemicals) was then used and the reaction product visualised
using enhanced chemiluminescence (ECL, Amersham-Pharmacia). Ex-
pression of SAP kinases was determined by Western blotting using
anti-myc antibody 9E10 (for SAPK2b/p38L, SAPK3/p38Q and
SAPK4/p38N), as well as anti-SAPK1/JNK and anti-SAPK2a/p38K
antibodies (Santa Cruz Biotechnology). The phosphorylation state
of tau was monitored using the phosphorylation-dependent anti-tau
antibodies AT270, AT8, AD2 and AP422 (Fig. 1) [12,16,36,37]. Tau
levels were determined using antiserum 134 [5], which recognises the
carboxy-terminus of tau in a phosphorylation-independent manner.
Band intensities were quanti¢ed using densitometry (Molecular Dy-
namics).
3. Results
COS cells were transfected with the tau construct alone or
with the tau/SAP kinase/SAP kinase kinase constructs. After 2
days, the cells were exposed to osmotic stress using sorbitol,
followed by analysis of the phosphorylation state of tau using
anti-tau antibodies. Preliminary experiments had established
that similar levels of each SAP kinase were expressed in COS
cells 2 days after transfection (not shown). In cells transfected
with the tau construct alone, a slightly reduced gel mobility of
tau protein was observed following sorbitol treatment. How-
ever, this was not accompanied by a signi¢cant change in
phosphorylation at the epitopes recognised by anti-tau anti-
bodies AT8, AT270, AD2 and AP422 (Fig. 2). Following
transfection of the tau/SAP kinase/SAP kinase kinase con-
structs and osmotic stress, tau protein showed a greatly re-
duced gel mobility and an increased phosphorylation at the
sites recognised by AT8, AT270, AD2 and AP422 (Fig. 2).
The labelling given by each phosphorylation-dependent anti-
tau antibody was quanti¢ed and normalised to that given by
the phosphorylation-independent anti-tau serum 134, to cor-
rect for variations in tau levels. As shown in Fig. 3, of the ¢ve
SAP kinases tested, SAPK3/p38Q had the largest e¡ect on the
phosphorylation of tau, followed by SAPK4/p38N, SAPK2b/
p38L and SAPK2a/p38K. The e¡ect of SAPK1c/JNK1 was the
smallest.
Fig. 1. Epitopes of phosphorylation-dependent anti-tau antibodies.
A: Schematic diagram of the 441 amino acid isoform of human
brain tau with phosphorylated amino acids recognised by phosphor-
ylation-dependent anti-tau antibodies. The microtubule-binding re-
peat region of tau is shown in white. B: Phosphorylated residues in
tau recognised by each phosphorylation-dependent anti-tau anti-
body. All these antibodies recognise S/T-P sites in tau.
Fig. 2. Phosphorylation of tau protein by SAP kinases in trans-
fected COS-7 cells. Lanes: 1, transfected tau; 2, transfected tau+os-
motic stress; 3, transfected tau, SAPK1c/JNK1 and MKK4+osmotic
stress; 4, transfected tau, SAPK2a/p38K and MKK6+osmotic stress;
5, transfected tau, SAPK2b/p38L and MKK6+osmotic stress;
6, transfected tau, SAPK3/p38Q and MKK6+osmotic stress; 7, trans-
fected tau, SAPK4/p38N and MKK6+osmotic stress. Tau phosphor-
ylation was assessed using phosphorylation-dependent monoclonal
anti-tau antibodies AT8 (A), AT270 (B), AD2 (C) and AP422 (D).
Tau levels were determined using the phosphorylation-independent
polyclonal anti-tau antibody BR134, which was used following each
monoclonal antibody incubation (E, F after AD2 and AP422, re-
spectively). A typical experiment is shown. Similar results were ob-
tained in ¢ve separate transfection experiments.
Fig. 3. Quantitative analysis of tau phosphorylation by SAP kinases
in transfected COS-7 cells. For each phosphorylation-dependent
anti-tau antibody, immunoreactivity was expressed as a percentage
of that given by the phosphorylation-independent antibody BR134
(taken as 100%). Lanes: 1, 2, transfected tau; 3, transfected tau,
SAPK1c/JNK1 and MKK4; 4, transfected tau, SAPK2a/p38K and
MKK6; 5, transfected tau, SAPK2b/p38L and MKK6; 6, trans-
fected tau, SAPK3/p38Q and MKK6; 7, transfected tau, SAPK4/
p38N and MKK6. Sorbitol-induced osmotic stress is indicated (+).
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4. Discussion
SAP kinases are MAP kinase family members that are ac-
tivated by a variety of cellular stresses, by bacterial lipopoly-
saccharide and by the pro-in£ammatory cytokines interleukin-
1 and tumour necrosis factor [38]. The activation of SAP ki-
nases requires their phosphorylation on a threonine and a
tyrosine residue. Both phosphorylations are catalysed by
SAP kinase kinases that are themselves dependent on phos-
phorylation for activity. SAPK1c/JNK1 is activated by
MKK4 and MKK7, SAPK2a/p38K is activated by MKK3
and MKK6, whereas SAPK2b/p38L, SAPK3/p38Q and
SAPK4/p38N are activated by MKK6. SAP kinase mRNAs
are widely expressed, including in the brain.
In this study, we show that following transfection into COS
cells and osmotic stress SAPK1c/JNK1, SAPK2a/p38K,
SAPK2b/p38L, SAPK3/p38Q and SAPK4/p38N phosphorylate
tau protein to various extents, as judged by a reduced gel
mobility of phosphorylated tau and the generation of the epi-
topes of phosphorylation-dependent anti-tau antibodies
AT270, AT8, AD2 and AP422. All ¢ve SAP kinases generated
the AT270 epitope, indicative of phosphorylation of T181 in
tau. Quantitative analysis showed similar labelling with
AT270 for all the SAP kinases. This was not the case of anti-
bodies AT8, AD2 and AP422. For AT8, which recognises
phosphorylated S202 and T205 in tau, SAPK3/p38Q gave the
strongest labelling, followed by SAPK2b/p38L, SAPK4/p38N,
SAPK2a/p38K and SAPK1c/JNK1. The AD2 epitope, which
corresponds to phosphorylated S396 and S404 in tau, was
generated most e¡ectively by SAPK3/p38Q and SAPK4/p38N,
followed by SAPK2b/p38L, SAPK2a/p38K and SAPK1c/
JNK1. Finally, phosphorylation of S422 in tau, as recognised
by antibody AP422, was generated most e⁄ciently by SAPK3/
p38Q, SAPK4/p38N and SAPK2b/p38L, and less so by SAP-
K2a/p38K and SAPK1c/JNK1. S422 is an abnormal phos-
phorylation site, rather than a hyperphosphorylated site, since
it is phosphorylated in ¢lamentous tau, but not in tau from
control human brain [16]. SAP kinases may therefore play a
role in the abnormal phosphorylation of tau that is character-
istic of the tauopathies.
From the above, it follows that in transfected COS cells
tau is a good substrate for SAPK3/p38Q and SAPK4/p38N, a
reasonable substrate for SAPK2b/p38L and a relatively poor
substrate for SAPK2a/p38K and SAPK1c/JNK1. These ef-
fects mirror our previous ¢ndings [22] on the in vitro phos-
phorylation of tau protein by SAP kinases. One study has
described the e¡ects of osmotic stress on tau phosphorylation
in SH-SY5Y cells that had been transiently transfected with
SAPK3/p38Q or SAPK4/p38N [39]. Expression of SAPK3/
p38Q resulted in increased phosphorylation of tau at S396
and S404, in agreement with the present ¢ndings. However,
in contrast to the present ¢ndings, SAPK4/p38N had no sig-
ni¢cant e¡ect on the phosphorylation of tau. It appears
likely that the co-transfection of SAP kinase and SAP kinase
kinase provides a more sensitive measure for the study of tau
phosphorylation than the single transfection of SAP kinase.
Phosphorylation of tau negatively regulates its ability to in-
teract with microtubules [40]. It therefore appears likely that
phosphorylation by SAP kinases results in an increase in
soluble, unbound tau and a reduced stability of the micro-
tubule network. It remains to be determined whether SAP
kinases, in particular SAPK3 and SAPK4, play a role in the
normal phosphorylation of tau in developing and adult
brain.
SAP kinases may play a role in the abnormal hyperphos-
phorylation of tau in neurodegenerative diseases, since aber-
rantly activated SAPK1/JNK and SAPK2/p38 have been
found to be associated with cells that contain ¢lamentous
tau in Alzheimer’s disease, progressive supranuclear palsy,
corticobasal degeneration, Pick’s disease, FTDP-17 and
Gerstmann^Stra«ussler^Scheinker disease with tangles
[41^44]. Moreover, activated MKK6 has been described in
cells with neuro¢brillary lesions in Alzheimer’s disease, pro-
gressive supranuclear palsy and Pick’s disease [45]. It will be
important to determine whether these are early changes in the
pathway that leads from normal soluble to abnormal ¢lamen-
tous tau. If so, speci¢c inhibitors of SAP kinases could well be
of therapeutic bene¢t in the treatment of the tauopathies.
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